Nuvation Bio (NUVB) announced it has initiated an Expanded Access Program or EAP for taletrectinib in the U.S. for the treatment of patients ...
Augtyro (repotrectinib), a tyrosine kinase inhibitor (TKI) targeting ROS1 and NTRK, has been cleared for patients with ROS1-positive non-small-cell lung ... been given a ‘line-agnostic ...
These therapies focus on specific genetic mutations or molecular drivers, such as EGFR, ALK, ROS1 ... small cell lung cancer (NSCLC) whose disease progressed on 2 or more prior lines of standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback